BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Risdiplam (Evrysdi) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Risdiplam (Evrysdi)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05861999-10997@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Risdiplam (Evrysdi): Phase 4 readout est. (NCT05861999)
DESCRIPTION:Risdiplam (Evrysdi)\, phase 4\, Spinal Muscular Atrophy.\nStudy
 : A Study Evaluating the Effectiveness and Safety of Risdiplam Administere
 d in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Pla
 teau or Decline in Function After Gene Therapy\nEstimated primary completi
 on: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ri
 sdiplam-evrysdi#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05861999
URL:https://assetmemo.bio/drug/risdiplam-evrysdi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05861986-10997@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Risdiplam (Evrysdi): Phase 4 readout est. (NCT05861986)
DESCRIPTION:Risdiplam (Evrysdi)\, phase 4\, Spinal Muscular Atrophy.\nStudy
 : A Study Evaluating the Effectiveness and Safety of Risdiplam Administere
 d as an Early Intervention in Pediatric Participants With Spinal Muscular 
 Atrophy After Gene Therapy\nEstimated primary completion: 31 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/risdiplam-evrysdi#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05861986
URL:https://assetmemo.bio/drug/risdiplam-evrysdi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444476-10997@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20280623
DTEND;VALUE=DATE:20280624
SUMMARY:Risdiplam (Evrysdi): Phase 3 readout est. (NCT07444476)
DESCRIPTION:Risdiplam (Evrysdi)\, phase 3\, Spinal Muscular Atrophy.\nStudy
 : A Study to Learn About Salanersen's (BIIB115) Effects on Movement and It
 s Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy 
 (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With 
 Risdiplam\nEstimated primary completion: 23 June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/risdiplam-evrysdi#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07444476
URL:https://assetmemo.bio/drug/risdiplam-evrysdi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047144-10997@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Risdiplam (Evrysdi): Phase 2 readout est. (NCT07047144)
DESCRIPTION:Risdiplam (Evrysdi)\, phase 2\, Spinal Muscular Atrophy.\nStudy
 : A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 
 2 Years Old and Have Spinal Muscular Atrophy\nEstimated primary completion
 : November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/risd
 iplam-evrysdi#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07047144
URL:https://assetmemo.bio/drug/risdiplam-evrysdi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
